多病共存与基层心血管预防:新西兰队列研究
该队列研究纳入新西兰奥克兰地区ProCare初级卫生组织2014年登记的430 286名30-79岁无既往心血管疾病的成人,分析多病共存与不同心血管疾病风险组中双联降压降脂治疗 dispensing 的关联。结果显示多病共存者在各风险组均更可能接受并维持双联治疗,但高心血管风险人群中仍存在明显的证据-实践差距。
要点
- 多病共存者在低、中、高心血管风险组均更可能接受双联治疗。
- 低风险组多病共存者双联治疗维持率88%高于无多病共存者84%。
- 高心血管风险人群双联治疗使用仍不足,存在证据-实践差距。
核心结论
- 多病共存患者比无多病共存者更可能接受并维持指南推荐的心血管疾病预防治疗,但高心血管风险患者中仍存在明显的证据-实践差距。
研究设计与样本
- 研究为队列研究,纳入新西兰北岛奥克兰地区ProCare初级卫生组织2014年登记的430 286名30-79岁无既往心血管疾病的成人。
- 采用多变量泊松回归估计各心血管疾病风险组内接受双联治疗的相对风险(RR),并按多病共存状态比较双联治疗的两年维持情况。
主要发现
- 基线双联治疗 dispensing 率在低、中、高风险组分别为2.5%、31%和40%。
- 多病共存与接受双联治疗的可能性增加相关:低风险组RR 2.90(95%CI 2.77-3.03),中风险组RR 1.35(95%CI 1.32-1.38),高风险组RR 1.15(95%CI 1.10-1.22)。
- 基线接受双联治疗者中,低风险组多病共存者维持率88% versus 84%,中风险组90% versus 86%(均P<0.001);高风险组维持率相似(89% versus 88%,P=0.412)。
关键数值与推荐
- 新西兰Aotearoa临床指南推荐对大多数5年心血管疾病风险高(≥15%)者使用联合降压降脂治疗(双联治疗)。
- 对中等风险(5-14%)者推荐共享决策,对低风险(<5%)者一般不推荐双联治疗。
临床怎么用
- 在基层心血管预防中,应关注高心血管风险患者双联治疗的启动不足,尤其是不伴多病共存者可能被低估治疗。
- 对多病共存患者应继续维持指南推荐的双联治疗,同时注意其治疗维持率较高的特点。
局限性
- 研究为观察性队列,无法推断因果关系。
- 研究仅纳入新西兰奥克兰地区ProCare登记人群,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multimorbidity adds complexity to cardiovascular disease (CVD) prevention. Clinical guidelines in Aotearoa New Zealand recommend combined blood pressure- and lipid-lowering therapy ('dual therapy') for most people at high (≥15%) 5-year CVD risk; recommend shared decision making for those at intermediate risk (5-14%); and do not generally recommend dual therapy for those at low risk (<5%). AIM: To examine the association between multimorbidity and dispensing of dual therapy across CVD risk groups. DESIGN AND SETTING: Cohort study of patients enrolled in a primary health organisation serving the Auckland region of northern New Zealand. METHOD: The study included 430 286 adults aged 30-79 years without prior CVD who were enrolled in ProCare in 2014. Multivariable Poisson regression was used to estimate relative risks (RRs) for receiving dual therapy within each CVD risk group. Two-year maintenance of dual therapy was compared by multimorbidity status. RESULTS: Baseline dual therapy dispensing was 2.5%, 31%, and 40% in the low-, intermediate-, and high-risk groups, respectively. Multimorbidity was associated with a greater likelihood of receiving dual therapy across all risk groups (low risk: RR 2.90, 95% confidence interval (CI) = 2.77 to 3.03; intermediate risk: RR 1.35, 95% CI = 1.32 to 1.38; high risk: RR 1.15, 95% CI = 1.10 to 1.22). Among participants receiving dual therapy at baseline, maintenance was higher among those with multimorbidity in the low-risk group (88% versus 84%) and intermediate-risk group (90% versus 86%) (both P<0.001). In the high-risk group, maintenance was similarly high irrespective of multimorbidity (89% versus 88%; P = 0.412). CONCLUSION: Patients with multimorbidity were more likely to receive and maintain guideline-recommended CVD preventive therapy than those without multimorbidity. However, despite increasing use of dual therapy with increasing CVD risk, substantial evidence-practice gaps remained among patients at high CVD risk.
引用
- Mannheimer S, Choi YC, Poppe K, et al. Multimorbidity and cardiovascular prevention in primary care: a cohort study in New Zealand. Br J Gen Pract. 2026. PMID: 42097633. doi:10.3399/BJGP.2025.0798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。